Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 2/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1535995 | 0.93 | KMT2A (0.38) | KMT2AMEN1MAPK1BTKCTSL | |
| SCHEMBL3213624 | 0.90 | BTK (0.37) | KMT2AMEN1MAPK1BTKCTSL | |
| SCHEMBL1536186 | 0.90 | MEN1 (0.40) | KMT2AMEN1MAPK1BTKCTSL | |
| SCHEMBL18038894 | 0.88 | KMT2A (0.41) | KMT2AMEN1MAPK1BTKDPP8 | |
| SCHEMBL18216705 | 0.88 | BTK (0.35) | KMT2AMEN1MAPK1BTKCTSL | |
| SCHEMBL20940048 | 0.85 | HSD11B1 (0.39) | KMT2AMEN1MAPK1BTKCTSL | |
| SCHEMBL28961660 | 0.83 | KMT2A (0.38) | KMT2AMEN1MAPK1BTKCTSL | |
| SCHEMBL31640087 | 0.83 | CTSL (0.38) | KMT2AMEN1MAPK1CTSLDPP8 | |
| SCHEMBL29602537 | 0.82 | MEN1 (0.40) | KMT2AMEN1MAPK1BTKCTSL | |
| SCHEMBL29460260 | 0.82 | HSD11B1 (0.39) | KMT2AMEN1MAPK1BTKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313550-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2025-10-09 | — | — | US | disclosed |
| US-12365668-B2 | Aminopyrazine diol compounds as PI3K-y inhibitors | INCYTE CORPORATION (US) | 2025-07-22 | — | — | US | disclosed |
| WO-2025137622-A1 | AMIDOCYCLOALKYLENE NRF2 PROTEIN DEGRADERS | GANYMEDE ONCOLOGY, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250163030-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2025-05-22 | — | — | US | disclosed |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2025-05-08 | — | — | US | disclosed |
| WO-2025073583-A1 | PARP1 INHIBITOR COMPOUNDS | Duke Street Bio Limited (GB) | 2025-04-10 | — | — | WO | disclosed |
| US-20240400541-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2024-12-05 | — | — | US | disclosed |
| EP-4423078-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| CN-118290402-A | Aminopyrazine diol compounds as PI 3K-gamma inhibitors | 因赛特公司 | 2024-07-05 | — | — | CN | disclosed |
| US-10669262-B2 | Aminopyrazine diol compounds as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200102315-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2020-04-02 | — | — | US | disclosed |
| EP-3612517-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Tempest Therapeutics, Inc. (US) | 2020-02-26 | — | — | EP | disclosed |
| US-10479795-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2019-11-19 | — | — | US | disclosed |
| US-20190276435-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-09-12 | — | — | US | disclosed |
| US-20190119287-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2019-04-25 | — | — | US | disclosed |
| US-10138248-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors | INCYTE CORPORATION (US) | 2018-11-27 | — | — | US | disclosed |
| WO-2018195123-A1 | BICYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | TEMPEST THERAPEUTICS, INC. (US) | 2018-10-25 | — | — | WO | disclosed |
| US-20180009816-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | INCYTE CORPORATION | 2018-01-11 | — | — | US | disclosed |
| WO-2017223414-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS | INCYTE CORPORATION (US) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10479795-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines and substituted imidazo[1,2-b]pyridazines as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CA | KMT2A 2081/4885MEN1 1546/4885MAPK1 97/4885 |
| US-10669262-B2 | Aminopyrazine diol compounds as PI3K-γ inhibitors | PIK3CD, PIK3R5, PIK3CG | KMT2A 2796/4885MEN1 2318/4885MAPK1 137/4885 |
| US-12030885-B2 | Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3R5 | KMT2A 1693/4885MEN1 1542/4885MAPK1 130/4885 |
| US-20240400541-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | PIK3CD, PIK3R5, PIK3CG | KMT2A 2242/4885MEN1 2251/4885MAPK1 147/4885 |
| US-20200102315-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | KMT2A 2915/4885MEN1 1103/4885MAPK1 153/4885 |
| US-20190276435-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | PIK3CD, PIK3R5, PIK3CG | KMT2A 2242/4885MEN1 2251/4885MAPK1 147/4885 |
| US-20250163030-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | PIR, CYP3A43, CYP1A2 | KMT2A 2331/4885MEN1 719/4885MAPK1 1428/4885 |
| US-10138248-B2 | Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors | PIK3CA, PIK3CG, PIK3CD | KMT2A 1822/4885MEN1 1345/4885MAPK1 71/4885 |
| US-20250145594-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | KMT2A 4179/4885MEN1 4684/4885MAPK1 339/4885 |
| US-20190119287-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | KMT2A 2915/4885MEN1 1103/4885MAPK1 153/4885 |
| US-12365668-B2 | Aminopyrazine diol compounds as PI3K-y inhibitors | PIK3CD, PIK3R5, PIK3CG | KMT2A 2242/4885MEN1 2251/4885MAPK1 147/4885 |
| US-20180009816-A1 | HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS | PIK3R5, PIK3CA, PIK3CD | KMT2A 2915/4885MEN1 1103/4885MAPK1 153/4885 |
| US-20250313550-A1 | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS | PIK3CD, PIK3R5, PIK3CG | KMT2A 2242/4885MEN1 2251/4885MAPK1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.